Home › NDC Lookup › RxCUI directory › RxCUI 197949

Methsuximide 300 MG Oral Capsule — RxCUI 197949

RxNorm drug concept · Semantic clinical drug
RxCUI 197949 Semantic clinical drug · SCD ● Current RxNorm concept 2 FDA products 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI197949
Official nameMethsuximide 300 MG Oral Capsule
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped2
Package NDCs mapped2
Reported Medicaid activity (SDUD)417 prescriptions · 5 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Methsuximide: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It controls absence (petit mal) seizures, the brief ones that cause lapses of consciousness. It's used when other medicines haven't worked well enough.
  • You take it by mouth as a capsule. Your prescriber usually starts you low and raises the amount gradually to find what controls your seizures with the fewest side effects. Follow y...
  • Drowsiness, dizziness and unsteadiness are the most common. Some people get nausea, poor appetite, headache or trouble sleeping. Tell your doctor if they bother you.
  • Call right away for fever or sore throat, a rash or hives, confusion, or any new depression, mood changes or thoughts of self-harm. You'll also need regular blood, urine and liver...
📖 Read our full Methsuximide guide →

🕸️ Concept Web — How Methsuximide 300 MG Oral Capsule Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Methsuximide 300 MG Oral Capsule RxCUI 197949

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Methsuximide 47858
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Celontin 225235
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Methsuximide Oral Capsule 372846
    • Methsuximide Oral Product 1156726
    • Methsuximide Pill 1156727
    • Methsuximide Oral Capsule [Celontin] 366219
    • Celontin Oral Product 1166220
    • Celontin Pill 1166221
    • Oral Capsule 316965
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Methsuximide 300 MG SCDC · 316279
  • Methsuximide Oral Capsule SCDF · 372846
  • Methsuximide Oral Product SCDG · 1156726
  • Methsuximide Pill SCDG · 1156727

Brand-Name Concepts

  • Methsuximide 300 MG Oral Capsule [Celontin] SBD · 207088
  • Methsuximide 300 MG [Celontin] SBDC · 567882
  • Methsuximide Oral Capsule [Celontin] SBDF · 366219
  • Celontin Oral Product SBDG · 1166220
  • Celontin Pill SBDG · 1166221
  • Celontin BN · 225235

📦 FDA Products & Package NDCs

2 products · 2 package NDCs
2 package NDCs map to RxCUI 197949 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00071-0525-24 100 CAPSULE in 1 BOTTLE (0071-0525-24) Celontin Parke-Davis Div of Pfizer Inc 1957-02-08
70954-0228-10 100 CAPSULE in 1 BOTTLE (70954-228-10) Methsuximide ANI Pharmaceuticals, Inc. 2023-05-01
Observed labelers: ANI Pharmaceuticals, Inc. (1) · Parke-Davis Div of Pfizer Inc (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$4.4011
Range $4.4011–$4.4011 · middle 50% $4.4011–$4.4011 · 1 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.